169 related articles for article (PubMed ID: 30528227)
1. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Bhargava P; Kerr D; Alexanderian D
Mol Genet Metab; 2019 Feb; 126(2):121-130. PubMed ID: 30528227
[TBL] [Abstract][Full Text] [Related]
2. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Alexanderian D
Mol Genet Metab; 2021; 134(1-2):175-181. PubMed ID: 34247932
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
[TBL] [Abstract][Full Text] [Related]
5. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
[TBL] [Abstract][Full Text] [Related]
6. Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB.
Whitley CB; Vijay S; Yao B; Pineda M; Parker GJM; Rojas-Caro S; Zhang X; Dai Y; Cinar A; Bubb G; Patki KC; Escolar ML
Mol Genet Metab; 2019 Feb; 126(2):131-138. PubMed ID: 30635159
[TBL] [Abstract][Full Text] [Related]
7. Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B.
Whitley CB; Cleary M; Eugen Mengel K; Harmatz P; Shapiro E; Nestrasil I; Haslett P; Whiteman D; Alexanderian D
J Pediatr; 2018 Jun; 197():198-206.e2. PubMed ID: 29661560
[TBL] [Abstract][Full Text] [Related]
8. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
[TBL] [Abstract][Full Text] [Related]
9. High dose genistein in Sanfilippo syndrome: A randomised controlled trial.
Ghosh A; Rust S; Langford-Smith K; Weisberg D; Canal M; Breen C; Hepburn M; Tylee K; Vaz FM; Vail A; Wijburg F; O'Leary C; Parker H; Wraith JE; Bigger BW; Jones SA
J Inherit Metab Dis; 2021 Sep; 44(5):1248-1262. PubMed ID: 34047372
[TBL] [Abstract][Full Text] [Related]
10. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system.
Kim KH; Dodsworth C; Paras A; Burton BK
Mol Genet Metab; 2013 Aug; 109(4):382-5. PubMed ID: 23845234
[TBL] [Abstract][Full Text] [Related]
11. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
[TBL] [Abstract][Full Text] [Related]
12. Defective heparan sulfate metabolism in the Sanfilippo syndrome and assay of this defect in the assessment of the mucopolysaccharidoses patient.
Gordon BA; Feleki V; Budreau CH; Tyler L
Clin Biochem; 1975 Jun; 8(3):184-93. PubMed ID: 238759
[TBL] [Abstract][Full Text] [Related]
13. Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation.
Kresse H; Paschke E; von Figura K; Gilberg W; Fuchs W
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6822-6. PubMed ID: 6450420
[TBL] [Abstract][Full Text] [Related]
14. Clinical heterogeneity in Sanfilippo disease (mucopolysaccharidosis III) type D: presentation of two new cases.
Coppa GV; Giorgi PL; Felici L; Gabrielli O; Donti E; Bernasconi S; Kresse H; Paschke E; Mastropaolo C
Eur J Pediatr; 1983 Apr; 140(2):130-3. PubMed ID: 6411475
[TBL] [Abstract][Full Text] [Related]
15. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
[TBL] [Abstract][Full Text] [Related]
16. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
17. How close are we to therapies for Sanfilippo disease?
Gaffke L; Pierzynowska K; Piotrowska E; Węgrzyn G
Metab Brain Dis; 2018 Feb; 33(1):1-10. PubMed ID: 28921412
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys.
Pfeifer RW; Felice BR; Boyd RB; Butt MT; Ruiz JA; Heartlein MW; Calias P
Drug Deliv Transl Res; 2012 Jun; 2(3):187-200. PubMed ID: 25786866
[TBL] [Abstract][Full Text] [Related]
19. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
